Please use this identifier to cite or link to this item:
DC FieldValueLanguage
dc.contributor.authorJanse van Rensburg, Sen_US
dc.contributor.authorKotze, Maritha Jen_US
dc.contributor.authorCronje, Frans J.en_US
dc.contributor.authorDavis, Wen_US
dc.contributor.authorMoremi, Ken_US
dc.contributor.authorDashti, Jalali Sefid Men_US
dc.contributor.authorGamieldien, Junaiden_US
dc.contributor.authorGeiger, Den_US
dc.contributor.authorRensburg, Men_US
dc.contributor.authorVan Toorn, R.en_US
dc.contributor.authorDe Klerk, M.J.en_US
dc.contributor.authorHon, Gloudina Maryen_US
dc.contributor.authorMatsha, Tandi Edithen_US
dc.contributor.authorHassan, Mogamat Shaficken_US
dc.contributor.authorErasmus, Rajiv Ten_US
dc.identifier.citationJanse van Rensburg, S., Kotze, M. J., Cronje, F. J. et al. 2013. Biochemical markers for identifying risk factors for disability progression in multiple sclerosis. (In: SASOP Biological Psychiatry Congress, Port Edward, 29 August-1 September 2013). []en_US
dc.description.abstractBackground. Current therapeutic strategies for multiple sclerosis (MS), based on immune modulation, have modest efficacy in the prevention of disability. Objective. Pathology supported genetic testing (PSGT) was used to identify risk factors for disability progression and to guide personalised intervention to improve disease outcome in MS. Methods. Patients with MS (N=130) were assessed using lifestyle and diet questionnaires, as well as biochemical tests to identify markers for disability progression. Disability status was assessed using the Expanded Disability Status Scale (EDSS), ranging from 0 (no disability) to 10 (death due to MS). After following a personalised intervention programme that addressed the identified risk factors, patients were reassessed after 6 months, and again after 7 years. Results. At baseline, 30% of patients had non-anaemic iron deficiency, 65% had raised cholesterol values (>5.0 mmol/l), and 67% had high homocysteine levels. Vitamin D deficiency (<30 ng/ml) was found in 67% and vitamin D insufficiency (<50 ng/ml) in 81% of patients. In a pilot study with personalised intervention over 6 months, 12 compliant patients showed a significant improvement of 29.9% (the mean EDSS decreased from 3.50 to 2.45). After 7 years 12 compliant patients had a mean•}standard deviation (SD) EDSS of 1.4•}0.9. All of these patients scored ≤2.5, which is regarded as benign MS. Clinical improvement correlated with normalisation of blood parameters. Control subjects (n=12) who were not compliant, had a mean•}SD EDSS of 8.4•}1.5 after 7 years (difference significant, p<0.0001).en_US
dc.subjectBiochemical markersen_US
dc.subjectrisk factorsen_US
dc.subjectdisability progressionen_US
dc.subjectmultiple sclerosisen_US
dc.subjecttherapeutic strategiesen_US
dc.titleBiochemical markers for identifying risk factors for disability progression in multiple sclerosisen_US
dc.relation.conferenceSASOP Biological Psychiatry Congress, Port Edward, 29 August-1 September 2013en_US
Appears in Collections:HWSci - Conference Papers
Files in This Item:
File Description SizeFormat 
Biochemical markers for identifying risk factors for disability progression in multiple.pdfAbstract312.84 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM



Items in Digital Knowledge are protected by copyright, with all rights reserved, unless otherwise indicated.